INC Research ($INCR) has started what it says is the industry's first site advocacy group, gathering study investigators to discuss how to improve speed and results in R&D.
The group, formed in partnership with the Society for Clinical Research Sites, brings in investigators with at least 10 years of experience in CNS trials, INC said, and its members will meet to discuss study design and make recommendations to the CRO. According to a 2012 Tufts study, CNS drugs take 35% longer to develop than other treatments, and INC believes better dialog between sponsors, CROs and sites can help avoid such costly delays.
"Through this forum, INC Research will collaborate with clinical research sites that have direct experience in psychiatry studies to gain their insights into the most common challenges and operational efficiencies that can be implemented for future studies," Vice President Clare Grace said in a statement. "We will leverage these expert insights to incorporate the site and patient voice in the evaluation of psychiatry study protocols for scientific merit and operational success."
The effort builds on a 2014 deal with the Society for Clinical Research Sites in which INC joined the group at its highest membership level, giving the CRO a say in its future strategic initiatives. INC has also taken part in the society's training programs and backed an effort to foster communication between sites and sponsors.
Meanwhile, INC has posted steady revenue growth since pulling off a $150 million IPO last year. In the first quarter, the company boosted sales by 14.5% to $211.5 million while turning a $25.3 million net profit. The CRO is now expecting revenue between $880 million and $905 million for 2015, good for roughly 12% annual growth.
- read the statement